Can New Combo Fill ‘Unmet Need’ in R/R Hodgkin Lymphoma?

Acimtamig, a first-in-class CD30/CD16A bispecific innate cell engager (ICE), combined with an off-the-shelf cord-blood derived natural killer cell product (AlloNK), shows safety and efficacy in the treatment of patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, who otherwise have poor prognoses. “Acimtamig in combination with AlloNK shows promising efficacy with a well-managed safety profile …